Looking Into Meridian Bioscience's Return On Capital Employed
Meridian Bioscience (NASDAQ:VIVO) brought in sales totaling $67.77 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 125.52%, resulting in a loss of $7.34 million.